BiomX Inc. (PHGE)
BiomX Inc. is a biotechnology company focused on the development of microbiome-based therapies for various diseases. Utilizing its proprietary platform, it identifies and engineers beneficial bacteria to address conditions related to inflammation, metabolic disorders, and other chronic illnesses. The company aims to harness the microbiome's potential to offer novel, personalized treatment options.
Company News
BiomX initiated a Phase 2b clinical trial for BX004, a phage therapy targeting Pseudomonas aeruginosa infections in cystic fibrosis patients. The trial involves 60 patients and aims to evaluate bacterial reduction, lung function improvements, and quality of life metrics, with topline results expected in Q1 2026.
BiomX (PHGE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Here's what you need to know about trading penny stocks with $1,000 The post Trading Penny Stocks With $1,000, Top Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS guidance below estimates. Patterson posted adjusted earnings of 50 cents per share, missing market estimates of 58 cents per share. The company’...
The body's so-called germ squad in the gut can be tweaked, treating diseases including autism and Parkinson's disease.